Study Description
Per Health Authorities guidelines for gene therapy medicinal products that utilize
integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of
treated patients is required. The purpose of this study is to monitor all patients
exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion
to assess the risk of delayed adverse events (AEs), monitor for replication competent
lentivirus (RCL) and assess long-term efficacy, including vector persistence. Patients are enrolled following completion or early discontinuation from a Novartis
sponsored or supported study of CAR T-Cell treatment. Patients will be followed for 15
years post treatment from the last treatment. They will be monitored for safety and
efficacy within the primary treatment protocols for the protocol defined duration.
Patients can drop off treatment protocols at any time to enter this long term Follow up
study. Patients discontinuing from the primary treatment protocols for any reason will be
enrolled in this long term follow up (LTFU). This will allow collecting data on long term
safety and efficacy (as applicable) as mandated by the health authorities of all patients
treated with CAR-T therapy within the concept of a single protocol.
Collection of such long term effects of CAR-T cell therapy will help to further define
the risk-benefit profile of CAR-T Therapies.
Interventions
Previously treated CAR-T patients
Eligibility Criteria
Inclusion Criteria:
- All patients who have received a CAR-T therapy and completed or discontinued early
from a Novartis sponsored treatment protocol that utilized CAR-T cells or from any
CAR-T trial sponsored by the University of Pennsylvania with which Novartis has a
contractual agreement to co-develop the CAR technology.
- Patients who have provided informed consent for the long term follow up study prior
to their study participation .
Exclusion Criteria:
- There are no specific exclusion criteria for this study.
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.